Category: Archive

General Conditions of Sales

Posted on by Targeting Phage Therapy

Article 1. Subject

General terms of sale described below detail rights and duties between Targeting Phage Therapy, referred “the company”, selling the services defined below, and natural or legal person, referred “the customer”, buying one or several of these services through a contract as defined below.

Targeting Phage Therapy headquarters located in Tokyo, Japan, is authorized to handle all the conference logistics, payments and management.

Article 2. The contract

The order form or the completed registration form constitutes a proposal of contract on which the customer, or his possible representative, expressly states to have the power, the authority and the capacity in his conclusion and to the execution of the obligations it must assume.

The contract is formed and both committed parties from reception by the company society of the registration form or the order form. The latter must be duly signed by customer, stamped and shall bear the endorsement “Agreed and signed”.

Article 3. Conditions for changing

The company reserves the right to modify articles of general terms of sale at any time. Any new version shall enter into force the day following its on-line publishing on the website www.phagetherapy-site.com and will be applicable to any new proposal or to any endorsement issued after the date of its signature.

Article 4. Cancellation/ Modification policy

Part 1: Sponsors

Cancellation or modification of support items must be made in writing to Phage Therapy: contact[at]tid-site.com.

In case of cancellation or reduction of the Sponsorship Amount by Sponsor, the Organizer shall have the right to retain, and if not already paid, Sponsor must pay to Organizer, as agreed liquidated damages, the following amounts in according to the following time schedule, and Sponsor forfeits and waives any right or claim for a refund, in connection therewith:

  • 10% of the agreed package amount if the cancellation/ modification is made 6 months before the conference.
  • 50% of the agreed package amount if the cancellation/ modification is made 4 months before the conference.
  • 100% of the agreed package amount if the cancellation/ modification is made 2 months before the conference.

Part 2: Participants & Registration

All cancellations must be electronically mailed or postmarked.

4.1 The cancellation of participation in an event (except in case of Force Majeure) will be accepted if it is received at least 30 days before the event.

Cancellation fees to the amount of 50% plus 70€ for administrative fees will be retained.

Within 30 days before the event, no cancellation will be refunded.

4.2 Modifications from online participation to in-person participation will be charged the difference in amounts. However, modifications from in-person to online will not be refunded.

4.3 Substitutions are free of charge. You must submit a letter authorizing the transfer signed by the registered delegate two days before the event starting date

4.4 The participation fees for the dinner cannot be refunded.

4.5. The bank transfer fees 10€ will not be refunded.

Article 5. Prices

5.1 The rates of the sold services are those in effect the day of the sending of the order form or the registration form to the customer. They are denominated in euros. Registration Fees and Prices are mentioned including all taxes. No registration will be accepted without full payment

5.2 Registration fees include entrance to the conference, materials related to the conference, abstracts book of the conference and 1 lunch + 2 coffee/tea breaks (for 1 day-conference) or 2 lunches, 4 coffee/tea breaks (for 2 days-conference) or 3 lunches + 6 coffee/tea breaks (for 3 days-conference).

5.3 The company reserves the right to modify at any time its price list.

Article 6. Rights and duties

Part 1: Sponsors

6.1 50% of the payment must be done upon receipt of the sponsorship agreement and first invoice. The other 50% of the payment should be done 1 month before the event.

6.2 The full amount must be paid necessarily 30 days before the date of the event. The payment of contracts concluded after this date must be done before the beginning of the exhibition. The payment of the services is exclusively in euros:

– By credit card: A special code will be provided to you if you select this mean of payment.
– By bank transfer.

6.3 The payment of the services can be spread out subject to prior agreement of the company.

6.4 If the full payment is not made within the established period or mutual agreement between the parties, the sponsor will have to pay to the company interests on the total amount of 2,5 % per month since the date on which payment is due until having received the full payments by the company.

6.5 No discount will be given for advance payments.

Part 2: Participants

6.6 The full amount established (participation, additional registration) must be necessarily paid before the date of the event.

The settlement of the services is exclusively made in euros:

– By credit card: A special code will be provided to you if you select this mean of payment.
– By bank transfer.

6.7 If the full payment is not made during the established period or according to a mutual agreement granted between the parts, the company reserves the right to cancel the contract and to refuse the access to the event.

Article 7. Cancellation/Modification/Event postponing

Part 1: Event Modification

7.1 It may be necessary for reasons beyond control of Targeting Phage Therapy to change the content and timing of the program, the speakers, the date or the location of the conference without notice.

Part 2: Cancellation up to 45 days before the event

7.2 For any cancellation up to 45 days before the event, the company will propose two options:

– Cancellation of the contract and global refunds of the funds collected.

OR

– Postponing of the contract in the same conditions without any additional fees on the next year.

Virtual Option: The company has the possibility to decide whether to change the format of the event into virtual so that to avoid any cancellation. In this case, the conditions above cannot be applied.

The company will propose to adjust the service fees and two options to be chosen by the customer:

– Cancellation of the contract and global refunds of the funds collected.

OR

– Changing of the contract with fees adjustments without any fees of files.

Part 3: Cancellation 45 days before the event

7.3 For any cancellation 45 days before the event, the company will propose two options to the customer:

– Postponing of the contract in the same conditions without any additional fees on the next year.

OR

– Cancellation of the contract and global refunds of the funds collected including 10% fees of file.

Virtual Option: The company has the possibility to decide whether to change the format of the event into virtual so that to avoid any cancellation. In this case, the conditions above cannot be applied.

The company will propose to adjust the service fees and two options to be chosen by the customer:

– Cancellation of the contract and global refunds of the funds collected including 10% fees of file. The sponsors can only benefit from this option.

OR

– Changing of the contract with fees adjustments without any fees of files.

Part 4: Postponing of the event

7.4 The postponing of the event will imply a contract postponing at the new dates of the event and will allow no refunds. Targeting Phage Therapy is not responsible for covering airfare, hotel or other travel costs incurred by clients.

Part 5: Force Majeure

7.5 All situation resulting from unpredictable circumstance and preventing from the execution of the contract by both parties will pose a case of Force Majeure as mentioned on the Civil Code (Art. 1218, example, Pandemic).

If cancellation is done in case of Force Majeure, please refer to Part 3 of Article 7.

If postponing is done in case of Force Majeure, please refer to part 4 of Article 7.

Article 8. Rights and obligations of the company (regarding the sponsor)

8.1 The company agrees to use all the resources at its disposal to ensure customer satisfaction within the limits of the contractual services. If the present contract provides the right to the attribution of an exhibition area while respecting the individual wishes. However, the company reserves the right to modify the place in the event of absolute necessity, and this without the exhibitor being able to claim any damages.

8.2 Any decoration or special arrangement must be approved to the preliminary agreement or the prior approval of the company.

Article 9. The limitation of liability (regarding the sponsor)

9.1 The responsibility of each of the parties is limited to the engagements underwritten by them in the terms of the contract. By consequence the responsibility of the company cannot notably be engaged in the event of direct or indirect prejudice linked to the intervention outside the contract of one or several of the contractors.

9.2 In cases of force majeure, it becomes impossible to take possession of the premises to the date mentioned, the organizing committee would be required to refund the sums paid with the customer, less liabilities to prepare the event.

Article 10. Insurance and security (regarding the sponsor)

Sponsors must know the safety measures imposed by the public authorities.

The exhibitor must be compulsorily covered by a civil liability policy and an exhibitors damages coverage to property belonging to him.

The company disclaims any responsibility on the previous points. Whatever the cause or the nature of the damage, the sponsor and / or its subcontractors say they have renounced all claims against the company.

Article 11. Deterioration (regarding the sponsor)

Any damage to the building which hosts the event, the structures of the stands, soils exposed by the products will be charged to the sponsor in question.

Article 12. Attendees

The company reserves the right to expel any person whose attitude justifies such a measure.

Article 13. Application of the Regulation

The customer accepts these regulations and any new provisions that may occur, imposed by circumstances and adopted by the company in the interest of the event. Any violation of this regulation may result in the exclusion of a contravener client, without prior notice.

Article 14. Arbitration clause

14.1 The contracting parties agree that any dispute, disagreement, question or complaint arising from the implementation or interpretation of this agreement or related to it, directly or indirectly, be prepared and definitely goes to the Tokyo Commercial Court. The arbitration shall be conducted in accordance with the principles of equities.

14.2 Without prejudice to the foregoing, the company reserves the right to take such legal proceedings, if necessary, as a means of precaution to the jurisdiction that the contractors have their property.

Article 15. Final provision

15.1 This contract does not include under any circumstances the event program.

15.2 This contract may only be amended by both parties. Any notice submitted by one or other of the parties and / or any amendment made to this contract must be in writing and signed by the same individual who has signed this contract and must be accepted in all cases by both parties.

15.3 Partial changes will not make the contract invalid.

15.4 This contract will be effective on the date signed on the purchase order and / or the date of receipt by the company of the registration form.

Article 16. Copyrights

All intellectual property rights in all materials produced or distributed by Targeting Phage Therapy in connection with this event is expressly reserved and any unauthorized duplication, publication or distribution is prohibited.

Article 17. Data collection

Targeting Phage Therapy reserves the right to collect personal information and personal data about you. They are necessary for the management of the missions as well as for the improvement of the services and the information that we send to you. They may also be forwarded to the contributing companies responsible for the performance of the services and to the payment and to all subsidiaries of the company.

This information and data are also kept for security purposes in order to comply with legal and regulatory requirements.

In accordance with the law of 6 January 1978, you have the right to access, rectify and oppose personal data and personal data concerning yourself by sending an e-mail to the following address: contact[at]tid-site.com.

By accepting these Terms and Conditions, you agree and agree to abide by our privacy policy.

The data collected are intended for the use of the Platform. They are necessary for the processing and management of the service offered by the Platform to its Users.

Legal Mentions & Privacy Policy

Posted on by Targeting Phage Therapy

Website Editor & Owner

Targeting Phage Therapy
Kanaya Bldg 4F, 4-11-3,
Hatchobori Chuo-ku 104-0032
Tokyo – Japan

Hosting

Cloudflare

Credits and copyright

All rights of authors of protected works reproduced and communicated on this site are reserved. Unless authorized, any use of the works other than individual and private reproduction and consultation is prohibited.

Data collection

Targeting Phage Therapy reserves the right to collect personal information and personal data concerning you. They are necessary for the management of missions as well as the improvement of the Services and the information that we send you. They may also be transmitted to the contributing companies responsible for the execution of the Services and for payment as well as to all the subsidiaries of the company. This information and data is also kept for security purposes, in order to comply with legal and regulatory obligations under our privacy policy.

Privacy Policy

Foreword

In accordance with the Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, also called the General Data Protection Regulation (GDPR), which sets out the legal framework for processing personal data, we process personal data for the purposes of our business. To properly understand this policy:

  • The “controller” is Targeting Phage Therapy;
  • The “processor” is any physical person or legal entity who processes personal data on behalf of Targeting Phage Therapy;
  • “Data subjects” are customers and/or prospects of the services provided by Targeting Phage Therapy on its own behalf or for third parties;
  • “Services” are any event organized by Targeting Phage Therapy, or which Targeting Phage Therapy contributes to; any service or product;
  • An “event” is any face-to-face or virtual conference, convention, training workshop, seminar, webinar, etc.;
  • “Recipients” are physical persons or legal entities who receive personal data from Targeting Phage Therapy. The data recipients can be Targeting Phage Therapy employees or external organizations (third-party event organizers, partners, exhibitors, banking institutions, authorities, etc.).

Article 12 of the GDPR requires that data subjects be informed of their rights in a concise, transparent, intelligible and easily accessible form.

Purpose and Scope

The purpose of this policy is to meet Targeting Phage Therapy’s information obligation and formalize the rights and obligations of its customers and prospects regarding personal data processing for all of the services provided by Targeting Phage Therapy.

Targeting Phage Therapy is always committed to respecting privacy rights and protecting personal information. As such, we will ensure that all our activities involving the collecting, processing, use and sharing of personal data will adhere to the statements contained in this Privacy Policy. We are committed to abiding by all data protection laws in the countries in which we operate and we will be open and transparent in how we use, store, process and share your personal information.

Purpose of processing

Targeting Phage Therapy only processes the personal data of our customers and prospects collected by or for our services, or processed in connection with our services, in compliance with the general principles of the GDPR. Targeting Phage Therapy mainly processes your data to organize events and provide products and services. Data may be processed for the following purposes:

  • To promote our events and associated events;
  • Community management (users, members, customers);
  • To manage event registration and participation;
  • To manage applications for event participation funds;
  • To manage contributions to the events agenda;
  • To manage attendance and other certificates, invitation letters;
  • To manage purchases or subscription to other products and services online;
  • Statistics;
  • To manage requests to disenroll and unsubscribe;
  • To manage and meet user requests on our websites;
  • To personalize our communication via our customer marketing program in order to carry out marketing and promotional campaigns and gain a better understanding of your needs and wants;
  • To let you know about offers and products which we deem to be of legitimate interest to you or you have expressed an interest via either transactions or consumption of content;
  • To qualify our prospects and customer database, and segment customers based on web behavior on our websites;
  • To manage requests to unsubscribe from newsletters, promotions and satisfaction surveys;
  • To manage the right to modify/rectify/erase data or process requests to unsubscribe.

This list is meant to be as exhaustive as possible. Customers and prospects will be informed of any new purpose, alteration or removal of existing processing by an amendment to this policy.

Data collected: Type, Use and Consent

Data Source

  • When you register to the meeting
  • When you submit an abstract
  • When you accept to receive our Newsletter

Non-technical data (depending on use)

  • Identity (surname, first name, username, etc.)
  • Contact information (email and/or postal address)
  • Photo
  • Career information (profession, position, specialty, etc.)
  • Banking information, if necessary (e.g. for refunds)
  • Video images (filmed conferences, CCTV footage)

Technical data (depending on use)

  • Identification data (IP)
  • Connection data (including logs)
  • Click data
  • Location data
  • Tracking data (cookies on our websites, access to conference rooms)

The information that is provided by you and will be used only for the purposes stated, and will not be transmitted to others to third parties.

We may also collect some personal information about you indirectly, from other sources such as research companies, company websites and social media. As part of this process, we ask any third-party vendors to confirm that the information was legally acquired and that we have the right to obtain it and use it. This includes obtaining consent where legal regulations require explicit consent to be acquired prior to contact. As part of the process, we only aim to identify individuals who we believe will be interested in our products / services, contacting you on the basis of legitimate interest.

The information we collect on you may be used by us for marketing purposes. You may at any time choose not to receive marketing emails by selecting the unsubscribe option available on each email.

Targeting Phage Therapy is not responsible for losses of any kind resulting from illegal access to personal data. Furthermore, personal data may be communicated to any authority legally entitled to receive it. In this case, Targeting Phage Therapy is not responsible for the conditions under which the employees of these authorities access and use the data.

Cookies & Other Technologies

Google Analytics

We use Google Analytics to collect information about the use of our Services. Google Analytics collects information such as how often you visit the Services, which pages you visited when they do so, and which other sites they used prior to coming to our Services. We do not merge the information collected through the use of Google Analytics with personally identifiable data. Google’s ability to use and share information collected by Google Analytics about your visits to and use of the Services is restricted by the Google Analytics Terms of Service and the Google Privacy Policy. You can learn more about how Google collects and processes data specifically in connection with Google Analytics here. Further information about your option to opt-out of these analytics services is available here.

We do not have any agreements with any companies/organizations to analyze your visits and behavior.

Others

We also use technologies that help us determine whether you have opened an e-mail or clicked on a link contained in an e-mail. Collection of this information allows us to collect data on the effectiveness of our web sites and product offering and helps to personalize your experience and our interactions with you. If you wish for us not to use the data in this way then please email contact[at]tid-site.com.

Optional or mandatory information

All forms used to collect personal data use asterisks to inform customers and prospects whether information is mandatory or optional. If answers are mandatory, Targeting Phage Therapy explains the consequences of not providing an answer to customers and prospects.

Security

Targeting Phage Therapy is responsible for defining and implementing physical or logical security technical measures that it deems appropriate to prevent the unauthorized accidental or illegal destruction, loss, alteration or disclosure of data. These measures mainly include:

  • Data access control;
  • Use of an encryption protocol such as SSL for transferring data between user devices and the company’s servers;
  • Data hosting in data centers with maximum security;
  • Access to infrastructure via VPN – only certain preselected people are authorized to create a tunnel;
  • Regular and systematic application of security patches on infrastructure components.

Changes

This policy may be changed or amended at any time in the event of changes to legislation, case law, decisions and recommendation or uses. Customers and prospects will be informed of any new versions of this policy by any means chosen by Targeting Phage Therapy, including electronically (e.g. via email or online).

Right of transparency and being informed

Customers have a right to be informed about the collection and use of your personal data. Customers and prospects also have a right of access, provided the following rules are followed:

  • The request is issued by the person themselves, and is accompanied by a copy of a current piece of ID;
  • The request is made in writing and sent to the email address contact[at]tid-site.com.

Customers and prospects have the right to ask Targeting Phage Therapy for a copy of their processed personal data. However, if an additional copy is requested, Targeting Phage Therapy may require that customers and prospects bear the financial cost. If customers and prospects request a copy of their data via email, the information requested will be provided in standard electronic format, unless requested otherwise. Customers and prospects are also informed that their right of access does not apply to confidential information or data, or data which the law prohibits from being communicated. The right of access must not be exercised abusively, meaning on a regular basis for the sole purpose of disturbing the department in question.

Right of rectification

Targeting Phage Therapy meets update requests:

  • Automatically for online changes for fields which can be technically or legally updated;
  • On written request of the data subject, with proof of identity.

Right to erasure (Right to be forgotten)

You have, subject to certain conditions being met, the right to be forgotten. The right to erasure of customers and prospects does not apply if data is processed to comply with legal obligations. Where we can, we will remove all your details from our systems subject to being able to do so reasonably, and where no other legal or legitimate reason exists to keep your personal data.

Below are some restrictive cases:

  • If personal data is no longer required for the purposes for which it was collected or otherwise processed;
  • If the data subject withdraws consent to the original purpose for processing and there is no other justified reason for processing;
  • If the data subject is opposed to Targeting Phage Therapy processing their data for legitimate purposes and there is no legitimate urgent reason for processing;
  • If the data subject is opposed to their personal data being processed for prospecting and profiling purposes;
  • If personal data was illegally processed.

For security reasons, the relevant department must therefore verify your identity to prevent your confidential information from being communicated to someone other than yourself.

Right to restrict processing of your personal data

Customers and prospects are advised that this right is meant to be exercised if data is legally processed by Targeting Phage Therapy and if all the personal data collected is required for the performance of the sales agreement.

Right to data portability

Targeting Phage Therapy allows for data portability in the particular case of data communicated by the customers or prospects themselves, for online services provided by Targeting Phage Therapy itself and for purposes needing the sole consent of data subjects. In this case, data will be communicated in in a form that can easily be used by other systems.

Right of use

Customers and prospects grant Targeting Phage Therapy the right to use and process their personal data for the purposes stated above. However, Targeting Phage Therapy maintains ownership of enriched data produced from Targeting Phage Therapy processing and analysis (usage analysis, statistics, etc.). 

 

Paris Anti-Avian Influenza 2006 Agenda

Posted on by Targeting Phage Therapy

Objectives of Asian-European Conference on Avian Influenza 2006 :

The aim of this conference is to bring together world specialists in order to discuss the latest advances on Avian Influenza, especially on new therapeutic targets for treatment and prevention in humans, and the strategies to avoid a human pandemic. A special session will be reserved to discuss about the management of a catastrophic scenario, in the case of a pandemic outbreak.

Targeted audience :

The Asian-European Conference on Avian Influenza 2006 targets researchers and academic professors, R&D departments, clinicians, pharmaceutical companies, food supplement companies, veterinary medicine companies, marketing departments, investors, start ups, government regulators and actors of the economic environment.

Thematic Areas

  • Focus on H5N1
  • Treatments and perspectives for the fight against influenza
  • Prevention of influenza propagation in animals and humans
  • Disaster management response

Final Program

Thursday June 29

8h30 – Welcome

Session 1 : Introduction

Chairmen: Pr A. Osterhaus, Dr G. Rodier

8h50 – Conference Opening
Dr Felix Rey, Department of Virology, Institut Pasteur, Paris, France

9h00 – General Introduction
Recall of the facts: the origin of the avian epidemic, first concerned countries…
Latest data about the epidemic: how much countries concerned, how much human cases…
Conclusions of the November 2005 WHO meeting in Geneva, Switzerland
Dr Guenael Rodier, WHO Europe, Communicable Disease Surveillance and Response, Copenhague, Denmark

9h30 – Economic Impact of the Avian Influenza Propagation
Impact on the poultry industry and the global economy of South East Asia
Impact on public health worldwide
Dr Milan Brahmbhatt, the World Bank Group, Washington DC, USA

10h00 – The need of a global task force for influenza
Pr Albert Osterhaus, National Influenza Centre and Department of Virology, Erasmus Medical Centre Rotterdam, Rotterdam, The Netherlands

10h30 – Break and Poster Session

Session 2: Focus on H5N1

Chairmen: Dr M. De Jong, Dr D. Swayne

11h00 – The Widening Host Range and Changing Pathobiology of Eurasian H5N1 Avian Influenza in Domestic and Wild Birds
What are the clinical signs and lesions of the avian flu in poultry?
What is the kind of birds affected?
Ecology and changes in the H5N1 HPAI as expressed in broader avian host range
What adaptation of the virus to new bird species?
Dr David Swayne, Southeast Poultry Research Lab, Agricultural Research Service, Athens, Georgia, USA

11h30 – Influenza H5N1 : diagnosis and disease
What kind of diseases and consequences for human health?
What are the tools for early detection of the virus?
Pr Menno D. de Jong, Department of Virology, Oxford University Clinical Research Unit (OUCRU), Hospital for Tropical Diseases, Ho Chi Minh City, Viet Nam

12h00 – Risks of H5N1 mutations and mammalian adaptation
Dr Erich Hoffman, Department of Infectious Diseases, St. Jude Children’s Research Hospital, Memphis, USA

12h30 – Short Oral Communication

  • Importance of the receptor binding surveillance to detect the jumping of the host range of the highly pathogenic bird influenza virus (H5N1) into humans
    Yasuo Suzuki, College of life and Health sciences, Chubu University, Aichi, Japan

12h40 – Lunch and Poster Session

14h00 – Role of Mathematical Modelling in Pandemic Preparedness
What tools are used to make this kind of study?
What are the results of the latest modelling?
Based on these simulations, which kind of actions have to be applied to avoid a human pandemic?
Dr Simon Cauchemez, Department of Infectious Diseases Epidemiology, Imperial College London, United Kingdom

14h30 – Short Oral Communications

  • Pathogenesis of H5N1 a/vietnam/1203/04 in a mouse infection model
    James Long, Battelle medical research & evaluation facility, Columbus, USA
     
  • Distinct inhibition patterns of influenza a virus between the two most frequent alleles at the porcine MX1 locus
    Mélanie Palm, Faculty of Veterinary Medicine, University of Liège, Belgium
     
  • Clinical and laboratory comparison of human infections with dengue, influenza or avian influenza a (H5N1) viruses in Indonesia
    Herman Kosasih, Naval Medical Research Unit #2 (NAMRU-2) Jakarta, Indonesia

Session 3: H5N1 Detection, Treatments and Perspectives

Chairmen: Pr E. De Clercq, Dr L. Chernomordik, Dr E. Hoffmann

14h50 – Avian influenza in humans: existing treatments, their limits, and new perspectives
Tamiflu, Relenza, Amantadine, Rimantadine and others
Erik De Clercq, Virology and Chemotherapy Section, Department of Microbiology and Immunology, Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium

15h20 – Short Oral Communication

  • Increased sensitivity to Oseltamivir of neuraminidase of recent Influenza A (H5N1) Viruses
    Marie Anne Rameix-Welti, Unité de Génétique Moléculaire des Virus Respiratoires, Institut Pasteur, Paris, France

15h30 – Break and Poster Session

16h00 – Multivalent lectins as inhibitors of viral fusion and entry in cells: new antiviral mechanism
Pr Leonid Chernomordick, Section on Membrane Biology, Laboratory of Cellular and Molecular Biophysics, National Institute of Child Health and Human Development, Bethesda, Maryland,USA

16h30 – In silico docking on grid infrastructures to accelerate structure-based design against Influenza A Neuraminidases
Finding potential compounds that can inhibit the activities of Influenza A neuraminidase N1 subtype variants.
Accelerating the discovery of novel potent inhibitors through minimizing non-productive trial-and-error approaches.
Improving the efficiency of high throughput screening thanks to the grid infrastructure.
Dr Nicolas Jacq or Dr Vincent Breton, Laboratoire de Physique Corpusculaire of Clermont-Ferrand, CNRS/IN2P3, University of Clermont Ferrand, Aubière, France

17h00 – Electrochemical Influenza Surveillance System
Dr Amit Kumar, CombiMatrix Corporation President and CEO, Mukilteo,USA

17h15 – The use of real-time NASBA for the diagnosis of H5N1 Influenza and other respiratory viruses
Dr Guy Vernet, Director of the Emerging Pathogens R&D Department, Biomérieux, Marcy L’Etoile, France

17h30 – Short Oral Presentation

  • An alternative neutralization assay for H5N1 influenza a virus using retroviral pseudotypes
    Nigel Temperton, MRC/UCL Centre for Medical Molecular Virology, University College London, London, United Kingdom
     
  • Development of a real-time PCR assay for the detection of human influenza a (H5N1) virus and sequence comparison of three avian influenza a (H5N1) detected in Switzerland
    Yves Thomas National Centre of Influenza, University Hospital of Geneva, Geneva, Switzerland
     
  • THE NA-STAR® influenza neuraminidase inhibitor resistance detection kit: chemiluminescence assay for detection and quantification of influenza neuraminidase activity
    Corinne Olesen, Applied Biosystems, Bedford, USA
     
  • Detection of avian influenza A/H5 viral isolates with highly sensitive, specific and inclusive real-time RT-PCR assays
    Olga Petrauskene, Applied Biosystems, Foster City, USA

18h00 – Discussion : What are the perspectives of Influenza treatment?
In the presence of the Scientific Committee

19h30 – Gala Dinner
On the Seine, on board of the cruising restaurant boat “Le Capitaine Fracasse”

Friday June 30

Session 4: How to prevent Human and Avian Influenza

Chairmen: Pr S. Van der Werf, Dr S. Sambhara

9h00 – The international response on avian influenza
The terrestrial animal health code
International standards
Vaccination
Short/medium and long term actions on global, regional and national level
Dr Christianne Bruschke, OIE, Paris, France

9h30 – Strategies to prevent avian influenza in humans in a non pandemic frame
How to avoid the transmission of the virus from animal to human?
Isolation in health care facilities
Health care worker exposures
Precautions for household and close contacts
Precautions for travelers
Pr Didier Houstin, Interministry Delegate for the Fight against Avian Influenza, French Ministry of Health, Paris, France

10h00 – Prevention through immunization: latest advances on vaccination
New adjuvants
Reverse genetics
Pr Sylvie Van der Werf, Génétique Moléculaire des Virus Respiratoires – URA 1966 CNRS, Pasteur Institute, Paris, France

10h30 – Break and Poster Session

11h00 – Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice
Dr Suryaprakash Sambhara, Centers for Disease Control and Prevention, Atlanta, USA

11h30 – Short Oral Communications

  • A new approach for an influenza virus live vaccine by modification of the cleavage site of the haemagglutinin by reverse genetics
    Juergen Stech, Institute of Virology, University Hospital Giessen-Marburg, Germany
     
  • Development of vaccines against pandemic influenza : Safety, immunogenicity and prospects of an inactivated split-virion H5N1 influenza vaccine
    Dr Agnes Hoffenbach, Influenza Franchise Program Leader, Sanofi Pasteur, Marcy l’Etoile, France
     
  • Respiratory protection against avian influenza
    Pierre Jean Messier, Triosyn Corporation , USA

11h50 – Antiviral effect of catechins in green tea on influenza virus
Pr Baik-Lin Seong, Department of Biotechnology, College of Engineering, Yonsei University, Seoul 120-749, South Korea

12h20 Pandemic Influenza: a potential role for statins in treatment and prophylaxis
Pr David Fedson, Former Professor of Medicine, University of Virginia School of Medicine, Sergy Haut, France

12h35 – Short Oral Communication

  • Subtype-diverse inactivation of influenza A viruses including H5N1 with an extract of Trifolium species and pomegranate juice
    Girish Kotwal, Division of Medical Virology, Institute of Infectious Diseases and Molecular Medicine (IIDMM), University of Cape Town School of Medicine, Cape Town, South Africa

12h40 – Lunch and Poster Session

Session 5: Disaster Management Response

Chairemen: Pr F. Bricaire, Pr K Van der Velden

14h00 – How to manage a Human Pandemic of Avian Influenza? Is Europe ready?
What are the different phases of a pandemic?
What are the measures set up by the governments?
What are the recommendations for individuals and public organisms in case of a pandemic?

14h30 -Ethical Challenges in Pandemic Planning
How to minimize the differences in means between rich and poor countries in the fight against a pandemic?
How and to whom should the doses of vaccines be distributed in priority: to infected patients or in prevention to people important for the maintenance of the economical?
How to avoid or minimize the impact of travel restrictions and quarantine?
Dr Ross E.G. Upshur, Joint Centre for Bioethics Flu Pandemic Working Group Member, University of Toronto, Toronto, Canada

15h00 – Round Table Discussion in presence of emergency medical doctors, general medical doctors, crisis management specialists and the scientific committee: is the medical profession ready to fight against a pandemic? Is the world ready to face a human avian flu pandemic?
Is the medical profession well informed and trained?
What are the recommendations for the health workers?
What are the solutions to face the vaccine shortage? (example: to improve the vaccine efficiency)
How to avoid a funnel effect in the emergency room?
What would be the ideal organization in the hospital to manage a pandemic?

Round Table Chairman: Pr Koos Van der Velden (Chairman of the European Influenza Surveillance Scheme)
In the presence of Dr Anne Mosnier, National Coordinator of the French Group of Regional Influenza Observation (GROG)

15h45 – Conclusion and Recommendations by the scientific committee

Paris Anti-Avian Influenza 2007 Agenda

Posted on by Targeting Phage Therapy

Objectives of Paris Anti-Avian Influenza 2007

After the great success of Paris Anti-Avian influenza 2006, the 2007 edition aims to bring again together the world specialists in the field in order to make a focus on avian influenza after the epidemic in 2006 and to discuss about the latest scientific advances, especially on new therapeutic targets for treatment and prevention (vaccines) in humans and animals, and the strategies to avoid a human pandemic by treating and preventing the epizootie.

 

Final Program

Thursday, May 31, 2007

8:30 – Welcome and registration

8:55 – Introduction
Pr Sylvie van der Werf, Institut Pasteur, Paris, France

Session 1 – Political and economic issues of Avian Influenza

9:00 – Avian Influenza and Human health: Focus on the situation one year after the worldwide outbreak
Dr Keiji Fukuda, Global Influenza Program, WHO, Geneva, Switzerland

9:30 – Economic impact of the avian influenza propagation
Mr Milan Brahmbhatt, Lead adviser in the east Asia region of the world bank, USA

10:00 – Avian influenza epizootie: The global situation; prevention and control strategies
Dr Bernard Vallat, OIE, Paris, France

10:30 – Break and poster session / Visit exhibition space

11:00 – Human-to-Human contamination: An increase in the cases number?
Pr Angus Nicoll, European Centre for Disease Prevention and Control, Stockholm, Sweden

11:30 – Estimation of potential global pandemic influenza mortality
Dr Christopher Murray, Harvard University, Cambridge, USA

12:00 – Discussion and remarks

12:15 – Poster session

12:40 – Lunch

Session 2 – Latest scientific advances on the H5N1 virus

14:00 – Functional genomics approaches reveal surprising mysteries of Influenza: What can the 1918 pandemic teach us about a possible H5 Avian Influenza outbreak?
Pr Michael G. Katze, University of Washington, Washington, USA

14:20 – Haemagglutinin mutations and binding of H5N1 to human-types receptors: one more step to the pandemic?
Pr Albert Osterhaus, National Influenza Centre and Department of Virology Erasmus Medical Centre Rotterdam, Rotterdam, The Netherlands

14:40 – Role of host cytokines responses in the pathogenesis of avian H5N1 influenza viruses in mice
Dr Terrence Tumpey, Centers for disease control and prevention, Atlanta, USA

15:00 – Can the structure of H5N1 neuraminidase lead to the design of new drugs?
Dr Rupert Russell, Centre for Biomolecular Sciences, St Andrews, United Kingdom

15:20 – Discussion

15:30 – Break and poster session

Session 3 – Latest scientific advances on H5N1 detection

16:00 – Diagnostic assay for H5N1 influenza viruses
Dr Nader Pourmand, Stanford University, Palo Alto, USA

16:20 – Effects of rapid real-time diagnostics on the spread of viral epidemics
Dr Jochen Kumm, Stanford University, Palo Alto, USA

16:30 – Short oral communications for sessions 1, 2 and 3

  • 16:30 Performance evaluation of five detection tests for Avian Influenza antigen with various Avian samples – Study results
    Dr Sze-Wee Tan, Rockeby Biomed Ltd, Singapore
     
  • 16:40 Nuclear and nucleolar targeting of influenza A virus NS1 protein: Striking differences between different virus subtypes
    Pr Ilkka Julkunen, Department of Viral Diseases and Immunology National Public Health Institute (KTL), Helsinki, Finland
     
  • 16:50 Sialic acid receptor binding of Influenza haemagglutinin proteins
    Dr Holly Shelton, School of Biological Sciences, University of Reading, United Kingdom

17:00 – Discussion and remarks

Gala Dinner

Friday June 1st, 2007

Session 4 – Prevention and treatments: Focus on vaccine and drugs development

9:00 – Overview on influenza vaccines and their clinical studies
Dr Martin Friede, Initiative for Vaccine Research, WHO, Geneva, Switzerland

9:30 – Pandemic influenza preparation: cross-reactive immunity with an adjuvanted H5N1 candidate vaccine
Dr Isabel Leroux-Roels, Center of Vaccinology, Ghent University and Hospital GlaxoSmithKline Biological, Ghent, Belgium

9:45 – Preclinical testing of adjuvanted-H5N1 candidate vaccines
Dr Catherine Caillet, Sanofi Pasteur, Marcy l’Etoile, France

10:00 – Inhibition of influenza virus infection by a novel antiviral peptide that targets viral attachment to cells
Dr Stacey Schultz-Cherry, Department of Medical Microbiology and Immunology University of Wisconsin, Madison, USA

10:30 – Break and poster session / Visit exhibition space

11:00 – Oseltamivir therapy in ferrets inoculated with H5N1 influenza viruses
Dr Elena Govorkova, St. Jude Children’s Research Hospital,Memphis, USA

11:20 – Last advances on Oseltamivir (Tamiflu): a medical and political point of view
Dr David Reddy, Influenza Task Force, F. Hoffmann-La Roche Ltd, Basel, Switzerland

11:40 – Short oral communications

  • 11:40 Influenza virus inhibitor against wild type and mutant neuraminidase
    Dr Jovan Pavlovic, Institute of Medical Virology, University of Zurich, Switzerland
     
  • 11:50 Synergistic inhibition of Avian (H5N1) highly pathogenic influenza virus by POLY I:POLY C12U combined with Oseltamivir or Zanamivir
    Dr D. Strayer, Hemispherx Biopharma, Inc., Philadelphia, USA
     
  • 12:00 Novel antivirals targeting influenza virus-specific membrane rafts Raft modulating aminosteroids as a new class of anti-influenza compounds
    Dr Cornelia Schroeder, Jado Technologies, Dresden, Germany
     
  • 12:10 T cell response to inactivated influenza vaccine in immunocompromised patients
    Dr Kathleen E. Sullivan, Chief, Division of Allergy and Immunology, Associate Professor of Pediatrics, The Children’s Hospital of Philadelphia, USA
     
  • 12:20 Replication deficient intranasal DEL-NS1 H5N1 influenza vaccine
    Dr Julia Romanova, Green Hills Biotechnology AG, Vienna, Austria
     
  • 12:30 Control of avian influenza vaccine potency through oil adjuvant design
    Dr Laurent Dupuis, Marketing & Development manager, Vaccine & Injectable Business Unit SEPPIC, Paris La Defense, France
     
  • 12:40 Immunization with Low Dose Adjuvanted Split H5N1 Pandemic Vaccine Protects Ferrets Against Homologous and Heterologous Challenge
    Dr Benoit Baras, GlaxoSmithKline Biologicals, Rixensart, Belgium

12:50 – Discussion and remarks

13:00 – Lunch

Session 5 – Prevention of Avian influenza in animals

14:00 – Avian influenza: State of the art Implementation of vaccination: the do’s and don’ts
Dr Christianne Bruschke, OIE, World Organisation for Animal Health, Paris, France

14:20 Early detection and application of preventive measures
Dr Stefano Marangon, Instituto Zooprofilattico Sperimentale delle Venezie, Padova, Italy

14:40 – Predicting the global spread of H5N1 avian influenza
Dr Marm Kilpatrick, Consortium for Conservation Medicine, New-York, USA

15:00 – Short oral communications for sessions 4 and 5

  • 15 :00 EFSA scientific opinion on vaccination against avian influenza if H5 and H7 subtypes in domestic poultry and captive birds
    Dr Oriol Ribo, Animal Health and Animal Welfare (AHAW) Unit, European Food Safety Authority (EFSA), Parma, Italy
     
  • 15:10 Novel polymer vaccine protects ferrets against lethal challenge with highly pathogenic avian influenza virus
    Dr Andrew Cawthon, Battelle Biomedical Research Center, West Jefferson, Ohio, USA
     
  • 15 :20 Regional risk assessment for the introduction of avian influenza in poultry producing farms
    Ms Barbara Grabkowsky, Institute for Spatial analysis and Panning in areas of intensive Agriculture (ISPA), University of Vechta, Germany
     
  • 15:25 The spread and evolution of highly pathogenic avian influenza (HPAI) H5N1 in Western Africa
    Dr Mariette Ducatez, Institute of Immunology, National PublicHealth Laboratory, Luxembourg
     
  • 15:30 Monitoring of HPAI H5N1 viruses in Russia (2006-2007)
    Dr Elena Yudina, Federal State Research Institution State Research Center of Virology and Biotechnology “VECTOR”, Koltsovo, Russia
     
  • 15:35 Detection of low pathogenic avian influenza virs un wild birds in Catalonia (Spain)
    Dr Núria Busquets Martí, Investigadora, Campus de Bellaterra,edifici CReSA, Barcelona, Spain
     
  • 15:40 Avian Influenza tool management
    M. Richard Martinez, Project Manager Europe, Middle East & Africa DuPont Chemical Solutions La Défense, France
     
  • 15:45 Pathologic and immunomodulatory effects of a specific nutrient synergy against avian flu virus
    Dr Steve Harakeh, Animal Sciences Department, American University of Beirut, Lebanon
     
  • 15:50 Elicitation of protective immune responses to pandemic H5N1 Influenza following immunization with A/Indonesia/05/2005 Virus-like particle vaccines
    Dr Rick A. Bright, Novavax Inc., Rockville, USA
     
  • 15:55 A new high-yielding and robust production system for vaccine production
    Ms Nathalie Landry, Medicago Inc.,Quebec, Canada

16:00 – Discussion and conclusion

Disaster Management Response

The following questions will be discussed with the speakers and chairmen:
Pr van der Werf, Institut Pasteur, France
Pr Koos Van der Velden, EISS, The Netherlands
Dr Déirdre Hollingsworth, Imperial college of London, United Kingdom

  • Pandemic preparation: is Europe ready? Can the pandemic be predicted?
  • What are the practical measures and ethical outcomes of a pandemic outbreak?
  • Controlling of pandemic influenza spread: the example of travel restrictions
  • Avian Influenza eradication: why is it so difficult?

16:45 – End of the conference